VKTX

Viking Therapeutics Inc

26.84

Nov 06 • 3:59 PM ET +1.05 (4.07%)

26.86

Aftermarket • 7:47 PM ET +0.02 (0.07%)

Healthcare Biotechnology USA Mid NASD

Peers: GPCR ALT MDGL SEPN LLY NVO RYTM AMGN WVE ARWR

| Held by: VTI XBI VB VBK VXF SCHA IWR VHT DFMC IWD

Scroll to Statements

Index	-
Market Cap	3.42B
Enterprise Value	2.72B
Income	-627.20M
Sales	0.00M
Book/sh	4.62
Cash/sh	7.53
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	53
IPO	Apr 29, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.81
P/C	3.57
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.27
Current Ratio	7.27
Debt/Eq	0.43
LT Debt/Eq	0.43
Option/Short	Yes / Yes

EPS (ttm)	-5.41
EPS next Y	-5.03
EPS next Q	-1.38
EPS this Y	-64.65%
EPS next Y	4.18%
EPS next 5Y	-7.24%
EPS past 3/5Y	-52.71% -42.46%
Sales past 3/5Y	- -
EPS Y/Y TTM	-155.21%
Sales Y/Y TTM	-
EPS Q/Q	-91.98%
Sales Q/Q	-
Earnings	Oct 28 AMC
EPS/Sales Surpr.	-45.81% -

Insider Own	2.93%
Insider Trans	-4.79%
Inst Own	59.68%
Inst Trans	1.88%
ROA	-73.07%
ROE	-96.37%
ROIC	-74.38%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	2.54%
SMA50	-9.91%
SMA200	-16.74%
Trades

Shs Outstand	127.52M
Shs Float	123.79M
Short Float	20.63%
Short Ratio	5.22
Short Interest	25.54M
52W High	43.15 -37.80%
52W Low	23.82 12.68%
Volatility	6.76% 6.05%
ATR (14)	1.78
RSI (14)	47.81
Beta	0.79
Rel Volume	0.55
Avg Volume	4.89M
Volume	2,668,177

Perf Week	-1.61%
Perf Month	-3.21%
Perf Quarter	-22.07%
Perf Half Y	-14.33%
Perf YTD	-23.71%
Perf Year	-27.98%
Perf 3Y	157.83%
Perf 5Y	311.03%
Perf 10Y	2638.78%
Recom	1.19
Target Price	95.32
Prev Close	25.79
Price	26.84
Change %	4.07%

Consensus

Strong Buy

Avg. Price Target

$95.32

Implied Upside

+255.1%

Analysts19incl. previous ratings

Rating Distribution16 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 15, 2026	Initiated	UUBS	Buy	$94	+250.2%
May 28, 2026	Initiated	LLake Street	Buy	$89	+231.6%
May 27, 2026	Resumed	TTruist	Buy	$83	+209.2%
Mar 26, 2026	Initiated	WWolfe Research	Peer Perform
Oct 29, 2025	Initiated	CCanaccord Genuity	Buy	$106	+294.9%
Apr 29, 2025	Initiated	CCantor Fitzgerald	Overweight	$104	+287.5%
Apr 08, 2025	Initiated	GGoldman	Neutral	$30	+11.8%
Feb 13, 2025	Initiated	BScotiabank	Sector Outperform	$102	+280.0%
Feb 07, 2025	Initiated	CCitigroup	Neutral	$38	+41.6%
Dec 02, 2024	Initiated	PPiper Sandler	Overweight
Nov 22, 2024	Initiated	RB. Riley Securities	Buy	$109	+306.1%
Nov 04, 2024	Reiterated	HH.C. Wainwright	Buy	$90 → $102	+280.0%
Sep 11, 2024	Initiated	JJP Morgan	Overweight	$80	+198.1%
Jun 27, 2024	Initiated	MMorgan Stanley	Overweight	$105	+291.2%
May 16, 2024	Upgrade	RRaymond James	Outperform → Strong Buy	$115 → $116	+332.2%
Mar 26, 2024	Reiterated	OOppenheimer	Outperform	$116 → $138	+414.2%
Mar 07, 2024	Initiated	JJefferies	Buy	$110	+309.8%
Feb 28, 2024	Reiterated	OOppenheimer	Outperform	$46 → $116	+332.2%
May 31, 2023	Resumed	RROTH MKM	Buy	$32	+19.2%
Mar 28, 2023	Reiterated	MMaxim Group	Buy	$15 → $25	-6.9%

Nov-03-26 04:30PM	Viking Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire) +7.21%
Oct-28-26 09:40PM	VKTX Stock Slides Overnight After Q3 Loss: CEOs Obesity Drug Launch Timeline Frustrates Retail (Stocktwits) +5.91%
06:29PM	Viking Therapeutics Misses As Spending Jumps, But Maintenance Data And A $960 Million Cash Pile Strengthen The VK2735 Story (Earnings Whispers)
05:42PM	Viking Therapeutics falls on third quarter loss miss (Investing.com)
04:05PM	Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
10:21AM	Loading…
10:21AM	After Wegovy and Zepbound, 6 weight-loss drugs in development (Quartz)
Oct-22-26 07:21AM	Viking Therapeutics Heads Into Q3 With Shares Near Lows And Spending Under The Microscope (Earnings Whispers)
Oct-21-26 04:05PM	Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026 (PR Newswire)
Oct-14-26 08:53AM	Vikings Key Obesity Pill Enters Phase 3 Trial Heres What Investors Need To Know (Stocktwits)
07:05AM	Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity (PR Newswire)
Oct-08-26 01:09PM	Analyst Predicts 316% Upside for Viking Therapeutics Stock Despite 30%+ Loss in Last 3 Months (TIKR)
Oct-06-26 07:05AM	Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity (PR Newswire)
Sep-28-26 11:29PM	Dow, S&P 500, Nasdaq Futures Fall Amid Rising Bond Yields, AI Concerns: KOD, SMMT, CLF, VKTX Stocks In Focus (Stocktwits) -7.11%
11:02PM	VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes Retail Calls Dip An Easy Buy Amid Buyout Talks (Stocktwits)
04:30PM	Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes (PR Newswire)
01:48PM	Loading…
Sep-24-26 01:48PM	One investor reportedly took a third of Vikings share sale (Investing.com) -11.76%
10:24AM	Viking Therapeutics Sinks 12% on Upsized $500 Million Raise (TIKR)
08:51AM	VKTX Stock Heads Toward Worst Day In Over A Year Just Days After Promising Weight Loss Drug Data Heres Whats Driving The Selloff (Stocktwits)
07:05AM	Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes (PR Newswire)
04:25AM	Nasdaq, S&P 500 Futures Slide As Treasury Yields, Trump-Xi Summit Keep Traders On Edge: META, GOOGL, SPCX, VKTX, SNAP, MCD, BB Stocks In Focus (Stocktwits)
Sep-23-26 10:24PM	VKTX Stock Eyes Blockbuster Week Despite Share Offering Retail Traders See A Stronger Hand In Buyout Talks (Stocktwits)
06:56PM	VKTX Stock Slides After-Hours On $400M Stock-And-Notes Raise After Tuesdays Rally (Stocktwits)
04:32PM	Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes (PR Newswire)
08:38AM	Viking Therapeutics Stock Surges 36% Following Weight Loss Drug Study Results (TIKR)
08:30AM	Entera Bio Receives New Overweight Rating From Cantor Fitzgerald (NASDAQ: ENTX) (FinanceWire)
08:28AM	6 'Moonshot' Biotech Stocks That Offer Big Risks, Bigger Rewards (Barrons.com)
07:37AM	The Stock Market Is Sleeping on the Next Big AI Catalyst (Barrons.com)
07:00AM	MARKETS LIVE: Futures slip ahead of Meta address (Proactive)
01:45AM	These 'Moonshot' Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right. (Barrons.com)
Sep-22-26 10:22PM	VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data Can Viking Win Over Wegovy And Zepbound Users? (Stocktwits) +35.67%
10:18PM	Loading…
10:18PM	Dow, S&P 500, Nasdaq Futures Climb Amid Iran Diplomacy Hopes, AI Rally: IONQ, VKTX, INFQ, BB Stocks In Focus (Stocktwits)
05:35PM	Lilly Rises Higher as Viking Preserves Up to 90% Monthly (GuruFocus.com)
05:26PM	Nasdaq Jumps To Close At Record As Chipmakers Climb, Oil Prices Cool AAPL, META, SPCX, MSFT, VKTX In Focus (Stocktwits)
04:34PM	Sandisk, Lennar, Viking Therapeutics, Shopify, GameStop, and More Stocks That Explain Today's Market (Barrons.com)
04:31PM	VKTX Stock Jumps 36% As Oppenheimer Hikes Target, Peers Call Data A Win (Stocktwits)
04:26PM	Viking Therapeutics Skyrockets On Obesity Drug Data. Lilly Rises, But Novo Falls. (Investor's Business Daily)
03:53PM	Viking Therapeutics Soars 36% on Clinical Trial Results: An Important Step (TIKR)
02:51PM	Beyond Eli Lilly and Novo Nordisk: Rising Obesity Drug Stocks to Watch (Barrons.com)
01:14PM	Viking Therapeutics VK2735 weight loss maintenance trial results (Quartz)
12:10PM	Viking shares surge on updated obesity drug data (BioPharma Dive)
11:46AM	This GLP-1 drug helped people maintain their weight loss in a clinical trial - even for those taking it once a month (MarketWatch)
11:24AM	Alibaba Higher on Chip News; On Holdings Football Move \| Stock Movers (Bloomberg)
11:05AM	Viking Therapeutics Stock Soars After Obesity Drug Delivers 22% Weight Loss (GuruFocus.com)
10:40AM	Viking Therapeutics shares surge over 27% on weight loss drug maintenance data (Proactive)
10:24AM	??Under the Rader: Viking Stock Gains on Weight-Loss Study (The Wall Street Journal)
10:07AM	Viking Therapeutics stock surges on promising weight-loss data: A closer look (Yahoo Finance Video)
09:49AM	Viking Therapeutics Stock Surges on Drug Trial Success (Schaeffer's Research)
09:39AM	Viking Therapeutics Shares Surge 27% Following VK2735 Weight-Loss Study Results (InvestorsHub)
09:07AM	Viking Soars as Obesity Shot Helps Cut Weight in Small Study (Bloomberg)
08:22AM	Viking Therapeutics Stock Surges 36%. It Could Challenge Lilly and Novo's Obesity Empire. (Barrons.com)
08:08AM	VKTX Stock Spikes 38% Premarket: Vikings VK2735 Shows Promise For Weight-Loss Maintenance (Stocktwits)
07:05AM	Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens (PR Newswire)
04:32AM	Nasdaq, S&P 500 Futures Pause After Record AI-Driven Rally: AMD, META, BABA, GME, HOOD, GRAB, VKTX Stocks In Focus (Stocktwits)
01:29AM	VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 Multi-Blockbusters (Stocktwits)
Sep-15-26 02:03AM	Can Viking Therapeutics Beat Big Pharma With Monthly Weight-Loss Shots? Heres The Risk CEO Says Could Derail It (Stocktwits) -5.01%
Sep-02-26 04:05PM	Viking Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-31-26 08:23PM	VKTX Stock Edges Higher In August Ahead Of Early-Stage Obesity-Drug Data Release In Q3 (Stocktwits)
Jul-30-26 01:00PM	VKTX Launches $500M Shelf After Full Enrollment Of Phase 3 Obesity Drug Study Retail Bets On Exceptionally Great Data (Stocktwits)
03:22AM	VKTX Stock Lags GLP-1 Peers In July But Viking CEO Says Its Obesity Drug Could Offer What Rivals Cant (Stocktwits)
01:03AM	Viking Therapeutics Inc (VKTX) (Q2 2026) Earnings Call Highlights: Advancing Obesity Pipeline ... (GuruFocus.com)
Jul-29-26 07:58PM	VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress (Stocktwits)
04:05PM	Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
Jul-23-26 07:05AM	Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors (PR Newswire) -5.15%
Jul-22-26 04:05PM	Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026 (PR Newswire)
Jul-21-26 09:00AM	A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up (PR Newswire)
Jul-17-26 06:39AM	The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea (Yahoo Finance)
Jul-15-26 08:45AM	As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22 (PR Newswire)
Jul-08-26 01:11AM	VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertexs $10B CRNX Deal? (Stocktwits) -5.15%
Jun-25-26 12:14AM	VKTX Stock Eyes Best Week In 2 Years: Retail Bulls Bet Q3 Obesity Data Could Put Novo, Big Pharma In Buyout Play (Stocktwits)
Jun-24-26 02:57PM	VKTX Stock On Track For Five Consecutive Days Of Gains Viking Launches Human Trial For Novel Obesity Drug VK3019 (Stocktwits) +8.79%
07:05AM	Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults (PR Newswire)
Jun-23-26 07:46PM	VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation (Stocktwits) +7.54%
Jun-11-26 07:05AM	Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer (PR Newswire)
Jun-02-26 07:43PM	VKTX Eyes Worst Week Since November As Trial Data Looms Wall Street Still Sees 200% Upside (Stocktwits) -6.33%
May-28-26 09:47AM	Dick's Sporting upgraded, Trade Desk initiated: Wall Street's top analyst calls (The Fly)
May-12-26 07:05AM	Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 (PR Newswire)
May-05-26 07:05AM	Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 (PR Newswire)
Apr-30-26 03:16AM	Viking Therapeutics Inc (VKTX) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
Apr-29-26 04:05PM	Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
Apr-22-26 04:35PM	Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026 (PR Newswire)
Apr-14-26 08:21PM	Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? (Quartz)
Apr-10-26 07:30AM	Viking Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Mar-26-26 07:05AM	Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 (PR Newswire)
Mar-10-26 02:32PM	Viking Therapeutics Stock Gets RS Rating Upgrade (Investor's Business Daily)
08:03AM	Is Viking Therapeutics (VKTX) One of the Shorted Biotech Stocks to Invest in (Insider Monkey)
Mar-09-26 09:05AM	NVO Stock Sheds Nearly $50B in Market Cap in a Month: Should You Sell? (Zacks)
Mar-05-26 05:45PM	Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
04:03PM	Viking Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
08:12AM	Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? (Zacks)
Mar-04-26 01:45AM	Raymond James Lowers Viking Therapeutics, Inc. (VKTX) Price Target Amid Optimistic Clinical Initiative Outlook (Insider Monkey)
Mar-02-26 08:50AM	Is Novo Nordisk's GLP-1 Dominance Fading After Lilly's Clinical Wins? (Zacks)
Feb-27-26 05:45PM	Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today (Zacks)
Feb-25-26 08:40AM	Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead? (Zacks)
Feb-24-26 12:00PM	Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026 (Zacks)
10:17AM	Viking Therapeutics, Inc. (VKTX): A Bull Case Theory (Insider Monkey)
Feb-23-26 04:11PM	Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin (Investor's Business Daily) +11.05%
02:29PM	Viking Therapeutics Stock Gains Amid Obesity Drug Buzz (Benzinga)
01:39PM	Banks, Asset Manager Stocks Plunge On Private Credit Panic: What's Moving Markets Monday? (Benzinga)
Feb-18-26 07:22AM	Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition? (Zacks)
Feb-17-26 11:04AM	Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk (Investor's Business Daily) +5.00%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lian Brian	President & CEO	Jul 29 '26	Sale	33.32	148,517	4,947,888	2,572,441	Jul 29 08:07 PM
ZANTE GREG	Chief Financial Officer	Jul 29 '26	Sale	33.47	21,217	710,141	212,204	Jul 29 08:06 PM
Mancini Marianna	Chief Operating Officer	Jul 29 '26	Sale	33.47	18,217	609,636	422,760	Jul 29 08:06 PM
BRIAN LIAN	Officer	Jul 29 '26	Proposed Sale	33.32	148,517	4,947,888		Jul 29 04:18 PM
GREG ZANTE	Officer	Jul 29 '26	Proposed Sale	33.47	21,217	710,141		Jul 29 04:04 PM
MARIANNA MANCINI	Officer	Jul 29 '26	Proposed Sale	33.47	18,217	609,636		Jul 29 04:03 PM
Aubuchon Neil William	Chief Commercial Officer	Mar 10 '26	Buy	33.50	4,475	149,912	4,475	Mar 10 06:20 PM
ZANTE GREG	Chief Financial Officer	Jan 05 '26	Sale	32.90	57,661	1,896,969	189,891	Jan 05 08:31 PM
Mancini Marianna	Chief Operating Officer	Jan 05 '26	Sale	32.98	57,661	1,901,405	409,190	Jan 05 08:31 PM
Lian Brian	President & CEO	Jan 05 '26	Sale	32.96	233,409	7,692,121	2,499,291	Jan 05 08:28 PM
FOEHR MATTHEW W	Director	Jan 02 '26	Option Exercise	3.33	16,000	53,280	148,036	Jan 05 08:25 PM
FOEHR MATTHEW W	Director	Jan 02 '26	Sale	35.11	16,000	561,694	132,036	Jan 05 08:25 PM
MARIANNA MANCINI	Officer	Jan 05 '26	Proposed Sale	32.98	57,661	1,901,406		Jan 05 04:32 PM
GREG ZANTE	Officer	Jan 05 '26	Proposed Sale	32.98	57,661	1,901,470		Jan 05 04:30 PM
BRIAN LIAN	Officer	Jan 05 '26	Proposed Sale	32.96	233,409	7,692,134		Jan 05 04:29 PM
MATTHEW W. FOEHR	Director	Jan 02 '26	Proposed Sale	35.11	16,000	561,694		Jan 02 04:46 PM

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

PresidentDr. Brian Lian Ph.D.

Chief Financial OfficerMr. Gregory S. Zante CPA

Vice President of Finance & AdministrationMr. Michael Morneau

Vice President of Quality & ComplianceMs. Katherine Mercier

Senior Vice President of CommercialMr. Kenneth J. Herman M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VKTX

Viking Therapeutics Inc

Upgrade your Finviz experience